8-K: Journey Medical Corporation Announces Full-Year 2023 Financial Results and Corporate Highlights

Journey Medical Corporation reported a 7% increase in total revenue for 2023, reaching $79.2 million, alongside significant cost savings and progress in their drug development pipeline.

Summary

• Journey Medical Corporation announced its financial results for the full year ended December 31, 2023, reporting total revenues of $79.2 million, a 7% increase compared to $73.7 million in 2022.
• The revenue increase was primarily driven by a $19.0 million upfront payment from a licensing agreement with Maruho Co., Ltd.
• Net product revenues decreased by $11.3 million, or 16%, due to lower unit volumes from legacy products and the discontinuation of Ximino.
• The company achieved $15.6 million in operating cost savings in 2023, exceeding their initial guidance of $12.0 million.
• Cost of goods sold decreased by $4.1 million, or 13%, to $26.7 million, due to lower product royalties.
• Selling, general, and administrative expenses decreased to $43.9 million from $59.5 million in 2022 due to cost reduction efforts.
• Research and development costs decreased to $7.5 million from $10.9 million due to the completion of Phase 3 clinical trials for DFD-29.
• The company reported a net loss of $(3.9) million, or $(0.21) per share, compared to a net loss of $(29.6) million, or $(1.69) per share in 2022.
• Adjusted EBITDA was $15.6 million, or $0.85 per share basic and $0.75 per share diluted, compared to $(7.3) million in 2022.
• Journey Medical's cash and cash equivalents totaled $27.4 million at December 31, 2023.
• The company entered into a $20.0 million credit facility with SWK Holdings Corporation, with an initial term loan of $15.0 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant improvements in financial performance, successful drug development milestones, and strategic partnerships. The company's cost-saving measures and reduced net loss are strong indicators of progress. However, the decrease in net product revenue and the need for a credit facility temper the overall sentiment slightly.

Positives

• The company achieved a 7% increase in total revenue, reaching $79.2 million for the full year 2023.
• Journey Medical exceeded its cost savings target, achieving $15.6 million in savings compared to the initial guidance of $12.0 million.
• The FDA accepted the NDA for DFD-29, a potential new treatment for rosacea, with a PDUFA goal date set for November 4, 2024.
• The licensing agreement with Maruho generated a significant upfront payment of $19.0 million.
• The company significantly reduced its net loss from $(29.6) million in 2022 to $(3.9) million in 2023.
• Adjusted EBITDA improved dramatically from $(7.3) million in 2022 to $15.6 million in 2023.
• The company secured a $20.0 million credit facility to support general corporate purposes and the potential launch of DFD-29.

Negatives

• Net product revenues decreased by $11.3 million, or 16%, due to lower unit volumes from legacy products and the discontinuation of Ximino.
• Cash and cash equivalents decreased by $4.6 million from $32.0 million at the end of 2022 to $27.4 million at the end of 2023.
• The company reported a net loss of $(3.9) million for the full year 2023, although this is a significant improvement from the previous year.

Risks

• The company's products are subject to regulatory approvals and clinical testing, which may not always be successful.
• A substantial portion of sales comes from products that may face generic competition, which could negatively impact operating income.
• The company operates in a heavily regulated industry, and future legislation could impact operations.
• The company's revenue is dependent on sales of dermatology products, and any setbacks could impair operating results.
• Competition could limit the commercial opportunity and profitability of the company's products.
• The company relies on third parties for several aspects of its operations.
• The company's success depends on the successful development and regulatory approval of DFD-29 and other future product candidates.
• Clinical trials may fail to demonstrate the safety and efficacy of product candidates.
• Competitors could develop and commercialize similar or identical products.
• The company faces risks related to the protection of its intellectual property.
• The company's business could suffer from computer system failures or cyber-attacks.
• There is substantial doubt about the company's ability to continue as a going concern.
• Major public health issues could impact product revenues and clinical trials.
• The company may need to raise additional capital.
• Fortress Biotech controls a voting majority of the company's common stock, which could be detrimental to other shareholders.

Future Outlook

The company believes it is well-positioned for growth and to bring significant value to patients, physician customers, and shareholders, particularly with the potential launch of DFD-29 in early 2025.

Management Comments

• Claude Maraoui, Journey Medical's Co-Founder, President and Chief Executive Officer, stated that 2023 was a year of growth and development for Journey Medical.
• He attributed the record high revenue to efforts to expand the reach of Qbrexza in Asia and continued sales of core dermatology products.
• He also highlighted the progress in advancing DFD-29 through late-stage clinical development.
• Management believes Journey is well-positioned for growth and to bring significant value to patients, physician customers, and shareholders.

Industry Context

This announcement reflects the ongoing efforts of pharmaceutical companies to develop and commercialize new treatments for dermatological conditions, particularly rosacea. The focus on cost efficiency and strategic licensing agreements is also a common trend in the industry.

Comparison to Industry Standards

• Journey Medical's 7% revenue growth is moderate compared to some high-growth biotech companies, but it is a positive sign given the challenges of generic competition.
• The $15.6 million in cost savings is a significant achievement, indicating effective operational management, which is crucial for smaller pharmaceutical companies.
• The successful NDA acceptance for DFD-29 is a major milestone, placing Journey Medical in a competitive position against companies like Galderma (Oracea) and others in the rosacea treatment market.
• The licensing agreement with Maruho is a strategic move to expand market reach, similar to other pharmaceutical companies that leverage partnerships for international growth.
• The improvement in Adjusted EBITDA from negative to positive territory is a strong indicator of financial turnaround, which is a key metric for investors in the pharmaceutical sector.

Related Party Transactions

• The balance sheet shows a 'Due to related party' liability of $195,000 in 2023 and $413,000 in 2022.

Stakeholder Impact

• Shareholders are likely to view the improved financial results and progress in drug development positively.
• Employees may benefit from the company's growth and stability.
• Customers (physicians and patients) may benefit from the potential launch of new treatments like DFD-29.
• Suppliers and creditors may see the company as a more stable and reliable partner due to its improved financial position.

Next Steps

• The company will hold a conference call on March 21, 2024, to discuss the financial results and provide a business update.
• The company is awaiting the FDA's decision on the NDA for DFD-29, with a PDUFA goal date of November 4, 2024.
• The company is preparing for the potential launch of DFD-29 in early 2025.
• The company will continue to execute its growth strategy and product development programs.

Key Dates

Keywords

dermatology, pharmaceutical, rosacea, DFD-29, Qbrexza, financial results, FDA, licensing agreement, cost savings, EBITDA